SCHEMBL2977692

SCHEMBL2977692

CN1CCCN(CCNc2ncnc3oc(-c4ccccc4)c(-c4ccccc4)c23)CC1

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.75
ALDH1A1 P00352 3/20 0.75
HPGD P15428 3/20 0.75
TSHR P16473 3/20 0.75
HSD17B10 Q99714 3/20 0.75
AURKA O14965 3/20 0.75
USP2 O75604 2/20 0.75
MAPK1 P28482 2/20 0.75
NPSR1 Q6W5P4 2/20 0.75
HTT P42858 1/20 0.75
LCK P06239 13/20 0.74
TNK2 Q07912 13/20 0.74
KDR P35968 3/20 0.74
MAPT P10636 1/20 0.67
EGFR P00533 2/20 0.66
SRC P12931 2/20 0.66
ZAP70 P43403 2/20 0.66
JAK3 P52333 2/20 0.66
LMNA P02545 1/20 0.61
PKM P14618 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2965895 0.96 AURKA (0.81) KDM4EALDH1A1HPGDTSHRHSD17B10
SCHEMBL2967784 0.92 KDM4E (0.84) KDM4EALDH1A1HPGDTSHRHSD17B10
SCHEMBL2972462 0.91 KDM4E (0.82) KDM4EALDH1A1HPGDTSHRHSD17B10
SCHEMBL2976570 0.89 AURKA (0.79) KDM4EALDH1A1HPGDTSHRHSD17B10
SCHEMBL2971629 0.86 ALDH1A1 (1.00) KDM4EALDH1A1HPGDTSHRHSD17B10
SCHEMBL2969946 0.85 LCK (0.92) KDM4EALDH1A1HPGDTSHRHSD17B10
SCHEMBL2976722 0.85 AURKA (0.76) KDM4EALDH1A1HPGDTSHRHSD17B10
SCHEMBL2962922 0.85 LCK (0.85) KDM4EALDH1A1HPGDTSHRHSD17B10
SCHEMBL2971610 0.85 AURKA (0.79) KDM4EALDH1A1HPGDTSHRHSD17B10
SCHEMBL2966394 0.85 LCK (1.00) KDM4EALDH1A1HPGDTSHRHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7776867-B2 Furanopyrimidines AMGEN INC. (US) 2010-08-17 US claimed
EP-1768986-A2 FURANOPYRIMIDINES Amgen Inc. (US) 2007-04-04 EP claimed
US-20060040961-A1 Furanopyrimidines AMGEN INC. 2006-02-23 US claimed
WO-2006004658-A2 FURANOPYRIMIDINES AMGEN INC. (US) 2006-01-12 WO claimed
US-7776867-B2 Furanopyrimidines AMGEN INC. (US) 2010-08-17 US disclosed
US-7776867-B2 Furanopyrimidines AMGEN INC. (US) 2010-08-17 US disclosed
EP-1768986-A2 FURANOPYRIMIDINES Amgen Inc. (US) 2007-04-04 EP disclosed
WO-2006004658-A2 FURANOPYRIMIDINES AMGEN INC. (US) 2006-01-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060040961-A1 Furanopyrimidines TYMS, IDO1, NFATC1 KDM4E 3284/4885ALDH1A1 159/4885HPGD 1536/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.